ES2562774T3 - Vacunas para la gripe basadas en el virus del mosaico de la papaya - Google Patents

Vacunas para la gripe basadas en el virus del mosaico de la papaya Download PDF

Info

Publication number
ES2562774T3
ES2562774T3 ES07845539T ES07845539T ES2562774T3 ES 2562774 T3 ES2562774 T3 ES 2562774T3 ES 07845539 T ES07845539 T ES 07845539T ES 07845539 T ES07845539 T ES 07845539T ES 2562774 T3 ES2562774 T3 ES 2562774T3
Authority
ES
Spain
Prior art keywords
mosaic virus
vaccines based
papaya mosaic
flu vaccines
papmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07845539T
Other languages
English (en)
Inventor
Denis Leclerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Folia Biotech Inc
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Application granted granted Critical
Publication of ES2562774T3 publication Critical patent/ES2562774T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un sistema presentador de antígeno que comprende uno o más antígenos del virus de la gripe en combinación con un virus del mosaico de la papaya (PapMV) o una VLP que comprende la proteína de cubierta de PapMV, en el que dicho uno o más antígenos del virus de la gripe no están conjugados con dicho PapMV o VLP.
ES07845539T 2006-11-15 2007-11-15 Vacunas para la gripe basadas en el virus del mosaico de la papaya Active ES2562774T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86599706P 2006-11-15 2006-11-15
US865997P 2006-11-15
PCT/CA2007/002069 WO2008058396A1 (en) 2006-11-15 2007-11-15 Papaya mosaic virus-based vaccines for influenza

Publications (1)

Publication Number Publication Date
ES2562774T3 true ES2562774T3 (es) 2016-03-08

Family

ID=39401290

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07845539T Active ES2562774T3 (es) 2006-11-15 2007-11-15 Vacunas para la gripe basadas en el virus del mosaico de la papaya

Country Status (7)

Country Link
US (1) US20100111996A1 (es)
EP (1) EP2069503B1 (es)
JP (2) JP2010508860A (es)
CA (1) CA2669485C (es)
DK (1) DK2069503T3 (es)
ES (1) ES2562774T3 (es)
WO (1) WO2008058396A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
EP1994139B1 (en) 2006-03-10 2016-07-13 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
CA2676481A1 (en) * 2007-01-26 2008-07-31 Folia Biotech Inc. Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
EP2442826B1 (en) * 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
CA2835972A1 (en) 2011-05-13 2012-11-22 Folia Biotech Inc. Virus-like particles and process for preparing same
AU2012331646B2 (en) 2011-11-02 2017-03-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Effect of an attenuated Bordetella strain against allergic disease
EP2827893B1 (en) * 2012-03-22 2017-11-29 Fraunhofer USA, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
CN104395346A (zh) * 2012-04-02 2015-03-04 弗利亚生物技术公司 重组木瓜花叶病毒外壳蛋白及其在流感疫苗中的应用
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
WO2014074509A1 (en) * 2012-11-07 2014-05-15 Vacplanta Limted Production of an immunogen using a plant virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
EP3141600A1 (en) * 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
JP6993984B2 (ja) 2016-03-29 2022-02-03 アンスティチュ パスツール ドゥ リール 変異ボルデテラ菌株および使用方法
WO2019077028A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille BORDETELLA STRAINS EXPRESSING SERO-TYPE FIMBRIAE 3
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
EP0652967B1 (en) * 1990-08-15 1998-02-04 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9227068D0 (en) * 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
CA2297786C (en) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
EP1135408B1 (en) * 1998-12-04 2011-09-21 Biogen Idec MA Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
JP4953570B2 (ja) * 2002-07-05 2012-06-13 フォリア バイオテック インコーポレイテッド アジュバントウィルス粒子
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
CA2669345A1 (en) * 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
CA2676481A1 (en) * 2007-01-26 2008-07-31 Folia Biotech Inc. Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof

Also Published As

Publication number Publication date
EP2069503B1 (en) 2016-01-06
US20100111996A1 (en) 2010-05-06
WO2008058396A1 (en) 2008-05-22
DK2069503T3 (da) 2016-02-15
JP2010508860A (ja) 2010-03-25
JP2013234198A (ja) 2013-11-21
EP2069503A1 (en) 2009-06-17
CA2669485A1 (en) 2008-05-22
CA2669485C (en) 2017-01-03
EP2069503A4 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
ES2562774T3 (es) Vacunas para la gripe basadas en el virus del mosaico de la papaya
EA201070066A1 (ru) Вакцины против гриппа с низким содержанием добавок
ES2621211T3 (es) Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
PH12018501602A1 (en) Subunit immersion vaccines for fish
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
CL2019002710A1 (es) Sistema y método para conjunto de jeringa y vástago de émbolo.
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
ES2564026T3 (es) Antígenos de micobacterias
ES2531634T3 (es) Procedimiento de comunicación en una red, dispositivo de comunicación y sistema asociado
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
PE20120630A1 (es) Inmunoconjugados dirigidos
AR066172A1 (es) Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica.
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
EA201001045A1 (ru) Модифицированный вирус гриппа
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
BR112013000394A2 (pt) composições e métodos para o tratamento de influenza
CL2013000670A1 (es) Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv.
CL2016000300A1 (es) Métodos terapéuticos
CO2018000171A2 (es) Metodos de purificacion y/o inactividad viral
AR084564A1 (es) Sistema aromatizador de aire
UY37198A (es) Vacuna universal para enfermedades virales
AR088220A1 (es) Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma